… long-term efficacy and safety of anti–tumor necrosis factor α agents (anti-TNF) in treating
cutaneous sarcoidosis is … tolerance of systemic agents in real-life psoriasis patients. The study …

… There are many dermatological hazards of tobacco use that … studies estimating that paradoxical
psoriasis can lead to anti-TNF … , but both presented severe rash relapse which confirms a …

… patients with moderate-severe PsA and active psoriasis who begun ustekinumab treatment
were … (IL)-23, IL-17, and tumor necrosis factor (TNF)-α is thought to play a key role in the …

… This study also evaluated the association between TNFi treatment duration and long-term …
to TNFi agents was found to be associated with reduced hazards for major CV events. …

… Long-term treatment was planned for 5 years. … adverse events were observed in this study
compared with the large secukinumab safety database across psoriasis, psoriatic arthritis, …

… Our aim was to review the literature on interleukins 12, 17, 23 and tumour necrosis factor-α …
Before introducing the biological treatment, in case of advanced to severe psoriasis, we …

… activity (MDA/VLDA)), and safety were assessed every 6 months. In addition to descriptive
… in the current study was heavily affected by comorbidities, chronic widespread pain, late …

… was to assess the benefit and safety of subcutaneous ustekinumab in a multicenter cohort of
patients with refractory anti-… trial performed in patients with moderate-to-severe psoriasis,18, …

… Anti-TNF therapy has also proved to have a favorable safety … was identified, the patient
was placed in the most-severe … extracted the genotypes for the known psoriasis (n = 36) and …

… tumor necrosis factor … analyses (NMA) were conducted to assess the comparative safety
profiles of FDA… oral treatments for patients with moderate-to-severe psoriasis who are eligible for …